Progen Co Ltd
296160
Company Profile
Business description
Progen Co Ltd is an R&D focused biopharmaceutical development venture. It is engaged in developing metabolic disease treatments, immune disease treatments, and immune anti cancer drugs using its immunology based drug development know how, and is focusing on developing inventive drugs through domestic and international open innovation.
Contact
172 Magokjungang-ro
7th Floor, Bio Innovation Park
Gangseo-gu
Seoul
KORT: +82 260982800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
50
Stocks News & Analysis
stocks
10 best US dividend aristocrats to buy now—including a surprise outperformer
These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.
stocks
Leading ASX players in this field look materially overvalued
We raise our Fair Value estimates but still think that current share prices rely on overly optimistic expectations.
stocks
After earnings, is Alphabet stock a buy, a sell, or fairly valued?
With a diverse portfolio of innovative technology and integrated media platforms, here’s what we think of Alphabet’s stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,999.00 | 16.40 | -0.18% |
| CAC 40 | 7,878.10 | 16.14 | 0.21% |
| DAX 40 | 24,395.74 | 133.52 | 0.55% |
| Dow JONES (US) | 44,461.28 | 171.71 | -0.38% |
| FTSE 100 | 9,166.43 | 29.49 | 0.32% |
| HKSE | 24,773.33 | 403.60 | -1.60% |
| NASDAQ | 21,129.67 | 31.38 | 0.15% |
| Nikkei 225 | 41,069.82 | 415.12 | 1.02% |
| NZX 50 Index | 12,823.74 | 32.23 | -0.25% |
| S&P 500 | 6,362.90 | 7.96 | -0.12% |
| S&P/ASX 200 | 8,742.80 | 13.60 | -0.16% |
| SSE Composite Index | 3,573.21 | 42.51 | -1.18% |